Fan JW, Xu SY, Wu J, Yu YW. Immune biomarkers as early indicators of renal damage in type 1 diabetic children: A step toward translational medicine. World J Diabetes 2025; 16(6): 106884 [DOI: 10.4239/wjd.v16.i6.106884]
Corresponding Author of This Article
Yong-Wei Yu, Department of Intensive Care Unit, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Shangcheng District, Hangzhou 310003, Zhejiang Province, China. yuyongwei@zju.edu.cn
Research Domain of This Article
Pediatrics
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Jun 15, 2025; 16(6): 106884 Published online Jun 15, 2025. doi: 10.4239/wjd.v16.i6.106884
Immune biomarkers as early indicators of renal damage in type 1 diabetic children: A step toward translational medicine
Jian-Wen Fan, Su-Yi Xu, Jun Wu, Yong-Wei Yu
Jian-Wen Fan, Su-Yi Xu, Jun Wu, Department of Nursing, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Jian-Wen Fan, Su-Yi Xu, Jun Wu, Department of Outpatient Care, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Yong-Wei Yu, Department of Intensive Care Unit, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Author contributions: Fan JW wrote the manuscript; Xu SY and Wu J collecting relevant references; Yu YW designed the study and revised the manuscript. All listed authors consent to the submission.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Wei Yu, Department of Intensive Care Unit, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Shangcheng District, Hangzhou 310003, Zhejiang Province, China. yuyongwei@zju.edu.cn
Received: March 10, 2025 Revised: April 4, 2025 Accepted: April 14, 2025 Published online: June 15, 2025 Processing time: 95 Days and 20.2 Hours
Abstract
An article recently published in the World Journal of Diabetes, provides valuable insights into using immune biomarkers to identify renal damage in pediatric patients with newly diagnosed type 1 diabetes (T1D). Although these findings are promising, clinical translation of these immune markers into routine diagnostics and preventive care remains challenging. In this letter, we propose building on the authors’ work by exploring the integration of immune biomarkers into a more comprehensive dynamic risk stratification model for early renal injury. Combining immune system indicators with metabolic and genetic factors could enhance the predictive accuracy and support more personalized interventions. Longitudinal studies are needed to evaluate temporal changes in immune biomarkers and their association with long-term renal outcomes in children with T1Ds. Immunomodulatory therapies targeting early immune dysfunction can prevent or slow the progression of diabetic nephropathy. By incorporating these aspects, we hope to translate immune biomarkers from research into practical clinical tools, ultimately improving patient outcomes and reducing the burden of kidney-related complications in pediatric diabetes.
Core Tip: Immune biomarkers play a crucial role in the early detection of renal damage in children with type 1 diabetes. This letter highlights the need for integrating immune indicators into a dynamic risk stratification model, combining metabolic and genetic factors for improved predictive accuracy. Additionally, we emphasize the importance of longitudinal studies to assess biomarker temporal dynamics and explore immunomodulatory strategies for early intervention. Advancing these approaches could enhance the clinical utility of immune biomarkers, facilitating their translation into routine diagnostics and personalized treatment strategies for diabetic nephropathy prevention.
